Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0310 -0.0087 (-21.91%)
Streaming Delayed Price Updated: 3:42 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 9 Next >
Lexaria Bioscience Corp. Provides Strategic Update
Via ACCESS Newswire
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Via ACCESS Newswire
Lexaria Attending BIO International Convention
Via ACCESS Newswire
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Via ACCESS Newswire
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Via ACCESS Newswire
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
Via ACCESS Newswire
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
Via ACCESS Newswire
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
Via ACCESS Newswire
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
Via ACCESS Newswire
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
Via ACCESS Newswire
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Via ACCESS Newswire
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Via ACCESS Newswire
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Via ACCESS Newswire
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
Via ACCESS Newswire
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Via ACCESS Newswire
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Via ACCESS Newswire
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Via ACCESS Newswire
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Via ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Via ACCESSWIRE
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Via ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
Lexaria's Human GLP-1 Study #5 Begins Dosing
Via ACCESS Newswire
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
Via ACCESS Newswire
Lexaria Releases Annual Letter from the CEO
Via ACCESS Newswire
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Via ACCESSWIRE
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Via ACCESSWIRE
Lexaria Forms New Scientific Advisory Board
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.